Reprint

Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges

Mechanistic and Therapeutic Challenges

Edited by
November 2019
348 pages
  • ISBN978-3-03921-706-9 (Paperback)
  • ISBN978-3-03921-707-6 (PDF)

This is a Reprint of the Special Issue Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs.

Format
  • Paperback
License and Copyright
© 2020 by the authors; CC BY license
Keywords
lung cancer; renal injury; fibrosis; crizotinib; anaplastic lymphoma kinase; cystic formation; pulmonary fibrosis; butylidenephthalide; SOX2; type I collagen; bleomycin; YAP; TAZ; Hippo pathway; fibrosis; cancer; mechanotransduction; TGF-β; Wnt; uterine fibroid; leiomyoma; tumor; tumor necrosis factor α; cytokine; growth factor; inflammation; clinical symptoms; pathophysiology; therapy; hepatocellular carcinoma; cirrhosis; regeneration; inflammation; cytokines; genetic instability; reactive oxygen species; idiopathic pulmonary fibrosis (IPF); lung cancer (LC); non-small cell lung cancer (NSCLC); acute lung injury; protein S; apoptosis; signal pathway; Erk1/2; lipopolysaccharide; uterine fibroid; leiomyoma; smooth muscle tumor of uncertain malignant potential; leiomyosarcoma; myometrium; immunohistochemistry; marker; pathology; tumor; diagnosis; cancer-associated fibroblasts; tumor microenvironment; nanoparticles; breast cancer; antitumor efficacy; cirrhosis; HBV; HCV; hepatocellular carcinoma; idiopathic pulmonary fibrosis; lung cancer; pathogenesis; common pathways; hepatocellular carcinoma (HCC); fibrosis; cancer-associated fibroblasts (CAFs); hepatic stellate cells (HSCs); tumor microenvironment; hepatocellular carcinoma; non-alcoholic steatohepatitis; fibrosis; hepatic stellate cells; extracellular matrix; carcinogenesis; angiogenesis; cancer-associated fibroblasts; extracellular matrix; fibrosis; heterogeneity; interstitial fluid pressure; metabolic reprogramming; transforming growth factor-β; tumor stiffness; GPR40; GPR120; DHA; omega-3 fatty acid; SREBP-1; hepatocytes; EMT; lncRNA; metastasis; miRNA; SMAD; TGF-β; targeted therapy; tumor microenvironment; n/a